Our group and others have developed a pharmacological TREM-1 blocker, LR-12, which has been shown to provide benefits in experimental chronic diseases, including atherosclerosis (16) and aortic aneurysm (34), as well as in acute injury, including sepsis and acute MI (15). Here, TREM1 is linked to Sepsis.